Skip to main content
. 2022 Sep 28;11(19):5742. doi: 10.3390/jcm11195742

Figure 3.

Figure 3

Percentage of patients treated with urate-lowering therapy reaching targeted serum-urate levels. Percentage of patients treated with febuxostat and allopurinol reaching serum-urate levels below (A) 6.0 and (B) 5.0 mg/dL, and percentage of allopurinol users treated with doses above restrictions according to estimated glomerular-filtration rates before the visit. * p < 0.01 in the mixed model.